Paul R. Edick, Director at Iterum Therapeutics plc (ITRM), bought 500 shares at $10.44 ($5K) on 2018-08-23, disclosed to the SEC on 2018-08-27.
Open-market purchase of $5k ITRM by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Something here stands out, but not much.
| Filing → |
| XERS | BUY | 2022-05-13 | $140K | — | Filing → |
| XERS | BUY | 2021-11-16 | $46K | — | Filing → |
| XERS | BUY | 2021-11-12 | $416K | — | Filing → |